AstraZeneca PLC $AZN Shares Acquired by Souders Financial Advisors

Souders Financial Advisors increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,638 shares of the company’s stock after buying an additional 751 shares during the quarter. Souders Financial Advisors’ holdings in AstraZeneca were worth $254,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of AZN. Brighton Jones LLC lifted its holdings in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of AstraZeneca by 7.5% during the 1st quarter. Bank of New York Mellon Corp now owns 994,084 shares of the company’s stock valued at $73,065,000 after buying an additional 69,557 shares during the last quarter. Penserra Capital Management LLC grew its stake in AstraZeneca by 7.6% during the 1st quarter. Penserra Capital Management LLC now owns 3,183 shares of the company’s stock worth $233,000 after buying an additional 226 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its stake in AstraZeneca by 213.9% in the first quarter. U.S. Capital Wealth Advisors LLC now owns 15,484 shares of the company’s stock valued at $1,138,000 after buying an additional 10,551 shares during the last quarter. Finally, Greenleaf Trust boosted its holdings in shares of AstraZeneca by 1.9% during the first quarter. Greenleaf Trust now owns 27,608 shares of the company’s stock valued at $2,029,000 after acquiring an additional 504 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ AZN opened at $83.77 on Friday. The business has a 50 day simple moving average of $81.31 and a two-hundred day simple moving average of $75.38. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $86.57. The stock has a market capitalization of $259.80 billion, a PE ratio of 31.49, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.08 earnings per share. On average, research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on AZN. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.